Okogen Secures $3.3 Million to Advance AI-Driven Conjunctivitis Treatment Platform
TL;DR
Okogen Inc. secures $3.3M in financing to advance Phase 2b program for AIC treatment, gaining a competitive edge in the eyecare market.
Okogen develops AI-driven image evaluation platform for telehealth, enhancing patient care and efficiency through comprehensive treatment solutions.
Okogen's innovative therapies for AIC aim to reduce healthcare costs, improve patient outcomes, and address unmet needs in managing this contagious condition.
Okogen relocates headquarters to Plano, TX, accelerating development of groundbreaking eyecare products and bringing cutting-edge solutions closer to critical resources.
Found this article helpful?
Share it with your network and spread the knowledge!
Okogen Inc. has announced the successful completion of $3.3 million in financing to advance the company through the completion of its Phase 2b clinical program for acute infectious conjunctivitis and the development of an AI-driven image-based evaluation platform designed for telehealth and at-home application. The funding supports Okogen's pivotal transition from a single-asset company focused solely on OKG-301 to a broader platform approach that combines a novel AI and image-based patient evaluation tool with the development of OKG-0303, a triple-combination eyedrop targeting both bacterial and viral conjunctivitis.
This milestone reinforces Okogen's commitment to delivering comprehensive therapeutic solutions for patients suffering from acute infectious conjunctivitis, a condition that affects millions of people annually across all age groups. The global market for treating acute infectious conjunctivitis is currently valued at $4.2 billion annually and is estimated to grow beyond $6.0 billion by 2031. Bacterial and viral conjunctivitis are easily spread from person to person if left untreated or improperly diagnosed, posing substantial healthcare costs and productivity losses.
The AI-enabled platform offers a comprehensive solution to aid in patient evaluation while delivering time and cost savings for patients, payers, and healthcare providers. By integrating evaluation and treatment, Okogen aims to address significant gaps in managing this highly contagious condition. There are currently no approved treatments for adenoviral conjunctivitis, which comprises over 90% of all viral ocular infections, making this development particularly important for patient care.
In line with its growth strategy, Okogen has relocated its headquarters from San Diego, California, to Plano, Texas, positioning the company closer to critical resources and infrastructure to further accelerate the development and commercialization of its groundbreaking therapies. A clinical data readout from the Phase 2b program is anticipated in Q4 2025. For more information, visit https://www.okogen.com.
Curated from Reportable
